Parkin (encoded by the PRKN gene) is a critically important E3 ubiquitin ligase that plays a central role in mitochondrial quality control through mitophagy. Loss-of-function mutations in PRKN are a major cause of autosomal recessive Parkinson's disease (PD), highlighting the essential role of this protein in dopaminergic neuron survival.
Parkin Protein is an essential component of the cellular machinery that maintains mitochondrial health. As an E3 ubiquitin ligase, Parkin orchestrates the selective elimination of damaged mitochondria through mitophagy—a process that is particularly crucial in neurons due to their high energy demands and post-mitotic nature. This page provides comprehensive information about Parkin's structure, function, mechanisms of action, and therapeutic implications for neurodegenerative diseases.
{{Infobox .infobox .infobox-protein
| protein_name = Parkin Protein
| gene = PRKN
| uniprot_id = O60260
| molecular_weight = ~52 kDa
| localization = Cytoplasm, mitochondria
| family = RING finger family, E3 ubiquitin ligase
}}
Parkin is a 465-amino acid protein with a complex multi-domain structure:
N-terminal Ubiquitin-like (Ubl) domain (residues 1-76): This domain is structurally similar to ubiquitin and regulates Parkin's E3 ligase activity. Under basal conditions, the Ubl domain folds back onto the core domains, autoinhibiting ligase activity. Phosphorylation events or binding to phosphorylated substrates can relieve this autoinhibition.
RING0 domain (residues 141-188): A unique domain found in Parkin family proteins that serves as a scaffold for protein interactions and contributes to the active site architecture.
RING1 domain (residues 212-277): Contains the first RING finger motif that coordinates two zinc ions. This domain interacts with E2 ubiquitin-conjugating enzymes.
In-between-ring (IBR) domain (residues 327-380): A conserved intermediate domain that plays a structural role in positioning the RING domains.
RING2 domain (residues 418-465): Contains the catalytic RING finger motif with the critical cysteine residues required for ubiquitin transfer. The RING2 domain also harbors the active site cysteine (C431) that forms a thioester intermediate with ubiquitin.
Cryo-EM studies have revealed that Parkin exists in an auto-inhibited "closed" conformation in the cytosol. The Ubl domain binds to the RING0 domain, preventing substrate access. Upon activation (e.g., by PINK1 phosphorylation), conformational rearrangements expose the catalytic domains, enabling substrate ubiquitination.
Parkin's primary function is in mitochondrial quality control through the PINK1-Parkin mitophagy pathway:
PINK1 stabilization on damaged mitochondria: Under normal conditions, PINK1 (PTEN-induced kinase 1) is imported into healthy mitochondria and degraded. Upon mitochondrial damage (e.g., depolarization, ROS damage), PINK1 accumulates on the outer mitochondrial membrane (OMM).
Phosphorylation of ubiquitin and Parkin: PINK1 phosphorylates ubiquitin at Ser65 and the Ubl domain of Parkin at Ser65. This phosphorylation activates Parkin's E3 ligase activity.
Recruitment to damaged mitochondria: Phospho-ubiquitin on the OMM recruits Parkin, where it becomes fully activated through conformational changes.
Substrate ubiquitination: Active Parkin ubiquitinates multiple OMM proteins, including MFN1, MFN2, VDAC1, TOM20, and MIRO proteins. This " ubiquitin code" marks damaged mitochondria for degradation.
Autophagic clearance: Ubiquitinated mitochondria are recognized by autophagy receptors (p62/SQSTM1, OPTN, NDP52) that link to the growing autophagosome via LC3, leading to lysosomal degradation.
Beyond mitophagy, Parkin participates in:
PRKN (also known as PARK2) was the first gene linked to autosomal recessive juvenile-onset Parkinson's disease. Over 200 pathogenic mutations have been identified, including:
PRKN mutations cause PD through loss of function:
Impaired mitophagy: Failure to eliminate damaged mitochondria leads to accumulation of dysfunctional mitochondria in dopaminergic neurons, increased oxidative stress, and ATP depletion.
Mitochondrial DNA damage accumulation: Damaged mitochondria with accumulated mtDNA mutations are not removed, leading to progressive respiratory chain dysfunction.
Synaptic dysfunction: Mitochondrial defects compromise synaptic energy supply, calcium buffering, and neurotransmitter recycling.
Increased susceptibility to stress: Neurons with impaired Parkin function show heightened vulnerability to toxins, neuroinflammation, and aging-related stress.
Patients with PRKN mutations exhibit:
Small molecules that activate Parkin's E3 ligase activity are under development:
The study of Parkin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. PMID:9581560
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257-273. PMID:25611507
Tanaka K, Suzuki T, Hattori N, Mizuno Y. Ubiquitin, parkin and Lewy bodies. Advances in Experimental Medicine and Biology. 2008;642:59-67. PMID:19181098
Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annual Review of Neuroscience. 2005;28:57-87. PMID:16022590
Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: from molecular mechanisms to therapy. EMBO Journal. 2012;31(14):3038-3042. PMID:22785037
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Reviews. 2005;48(2):390-401. PMID:15967427
Matsuda N, Tanaka K. Unveiling the physiological function of parkin. Autophagy. 2007;3(3):250-252. PMID:17404494
Sarraf SA, Raman M, Guarani-Pereira V, et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature. 2013;496(7445):372-376. PMID:23503661
Durcan TM, Fon EA. The three 'P's of mitophagy: PARKIN, phosphoubiquitin and phospho-ubiquitin. Journal of Molecular Biology. 2013;425(10):1800-1815. PMID:23664776
Shen J, Cookson MR. Mitochondria and dopamine toxicity in Parkinson's disease. Neuron. 2004;43(5):613-615. PMID:15339636